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ABSTRACT
Introduction The diaphragm is the main muscle of 
inspiration, and its dysfunction contributes to adverse 
clinical outcomes in critically ill patients. We recently 
reported the infiltration of SARS- CoV-2, and the 
development of fibrosis, in the diaphragm of critically 
ill patients with COVID-19. In the current study, we 
aimed to characterise myofiber structure in the 
diaphragm of critically ill patients with  
COVID-19.
Methods Diaphragm muscle specimens were 
collected during autopsy from patients who died of 
COVID-19 in three academic medical centres in the 
Netherlands in April and May 2020 (n=27). We studied 
diaphragm myofiber gene expression and structure and 
compared the findings obtained to those of deceased 
critically ill patients without COVID-19  
(n=10).
Results Myofibers of critically ill patients with 
COVID-19 showed on average larger cross- 
sectional area (slow- twitch myofibers: 2441±229 vs 
1571±309 µm2; fast- twitch myofibers: 1966±209 
vs 1225±222 µm2). Four critically ill patients with 
COVID-19 showed extremely large myofibers, which 
were splitting and contained many centralised nuclei. 
RNA- sequencing data revealed differentially expressed 
genes involved in muscle  
regeneration.
Conclusion Diaphragm of critically ill patients with 
COVID-19 has distinct myopathic features compared 
with critically ill patients without COVID-19, which may 
contribute to the ongoing dyspnoea and fatigue in the 
patients surviving COVID-19  
infection.
INTRODUCTION
In critically ill patients, diaphragm weak-
ness may develop and contribute to adverse 
clinical outcomes including ventilator 
weaning failure, prolonged hospitalisa-
tion and mortality.1 Diaphragm weakness 
in these patients is characterised by patho-
logical features in myofibers, including 
reduced cross- sectional area (CSA), that is, 
atrophy.2–4 Recently, we reported evidence 
for infiltration of SARS- CoV-2 in diaphragm 
myofibers.5 We also demonstrated increased 
expression of genes involved in fibrosis 
and histological evidence for the develop-
ment of fibrosis in the diaphragm of criti-
cally ill patients with COVID-19 compared 
with the diaphragm of critically ill patients 
without COVID-19.5 In the current study, 
we characterised myofiber structure in the 
diaphragm of critically ill patients with 
COVID-19. Myofiber structure is an impor-
tant determinant of diaphragm contrac-
tility. Consequently, impaired myofiber 
structure might contribute to diaphragm 
muscle weakness, and, thereby, impact 
weaning outcome and contribute to the 
persistent dyspnoea and fatigue reported in 
post- COVID-19 patients.6 Thus, we aimed to 
study the structure of diaphragm myofibers 
in critically ill patients with COVID-19 and 
compared the findings to those of patients 
without COVID-19.
Key messages
What is the key question?
 ► RNA- sequencing results from the diaphragm of 
deceased patients with COVID-19 suggest the ac-
tivation of gene pathways involved in myofiber 
regeneration.
What is the bottom line?
 ► In line with the RNA- sequencing results, the results 
of structural analyses of the diaphragm specimens 
show enlarged and splitting myofibers with central 
nuclei.
What read on?
 ► The diaphragm of deceased patients with COVID-19 
displays distinct pathological changes, which may 
contribute to the ongoing dyspnoea and fatigue in 
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Diaphragm specimens of critically ill patients with 
COVID-19 (COVID-19- intensive care unit (ICU), 
n=27) and of critically ill patients without COVID-19 
(control- ICU, n=10) were collected at autopsy. Diag-
nosis of COVID-19 was based on SARS- CoV-2 detec-
tion by real- time quantitative PCR, in nasopharyn-
geal swabs. Samples were obtained from the middle 
of the left costal diaphragm (figure 1A), 16–72 hours 
Figure 1 (A)Schematic of the location of the biopsy obtained (balck and yellow squares). (B) Volcano plot showing the 315 
upregulated and 281 downregulated genes (SPAAR: small regulatory polypeptide of amino acid response; SIK1: salt inducible 
kinase) and (C) Gene ontology biological process enrichment analysis (PANTHER) showing upregulated/downregulated 
processes in the diaphragm of COVID-19- ICU (n=11) patients compared with Control- ICU (n=3). (DEG: differentially 
expressed gene). (D) Cross- sectional area (CSA) in COVID-19- ICU (n=25) and Control- ICU patients (n=10). Representative 
images of one patient from Control- ICU (i) and COVID-19- ICU (ii), respectively. Cross- sections stained for fast myosin 
heavy chain isoforms (blue) to identify fast- twitch myofibers; slow- twitch myofibers are black; in green WGA to demarcate 
myofibers; bar=100 µm. Note the extremely large myofibers in the COVID-19- ICU patient (patient #28 is shown). Distribution 
of CSA of slow- twitch (iii) and fast- twitch (iv) myofibers of COVID-19- ICU patients (red) skewed towards larger CSA compared 
with Control- ICU patients (purple). The CSA of both the slow- twitch and fast- twitch myofibers were significantly larger in 
COVID-19- ICU patients compared with Control- ICU patients (v, vi). Data are visualised using histogram and violin plot. 
Each dot represents mean of the CSA from an individual patient. P values were obtained from linear mixed model analysis. 
(E) Quantification of CD68 +macrophages, CD45 + leucocytes, and MPO+ neutrophils in COVID-19- ICU and Control- ICU 
patients. No differences were observed between groups. The data are visualised using violin plot with each dot representing 
the value of an individual patient. P values were obtained from Mann- Whitney U test. (F) Signs of myofiber regeneration in 
COVID-19- ICU patients. (i) Quantification of the number of central nuclei in cross- sectioned myofibers. Note that four COVID-
19- ICU patients (#2;3;28;31) had an increased number of myofibers with 2–3 central nuclei; three of these four patients had 
myofibers with more than three central nuclei (up to 18 per myofiber). (ii) Cross- section of patient #31 stained with WGA and 
DAPI to localise the myonuclei; yellow numbers indicate representative myofibers with multiple central nuclei; bar=100 µm. (iii) 
H&E staining (formalin fixed sample) of a longitudinal section of patient #3 showing multiple ‘trains’ of central nuclei (arrows); 
bar=100 µm. (iv, v). Two serial cross- sections (separated by 100 µm) of patient #28, showing splitting of myofibers; arrows 
indicate the same myofibers with splitting events; in green WGA to demarcate myofibers. Also, note the large variation of 
myofiber CSA in this patient. In (v), α-MHC3 antibody staining (red) visualises myofibers expressing an embryonic isoform of 
myosin heavy chain. Note that the split fibers are adult, non- regenerating myofibers (white arrows) and that the tiny myofibers 
surrounded by fibrosis are regenerating (yellow arrows); bar=100 µm. (vi) Longitudinal section of patient #28 stained with WGA 
to demarcate the membrane (red) and DAPI to localise the myonuclei (white); the α-actinin antibody staining in green shows 
the Z- disc organisation. From left to the right, the diameters for the fibers are 40, 10 and 160 µm, respectively; bar=20 µm. 
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postmortem. Patients were recruited in three medical 
centres in the Netherlands. Clinical data were 
collected retrospectively.
Transcriptome sequencing (RNA-seq)
RNA and library preparation integrity were confirmed 
with a LabChip Gx Touch 24 (Perkin Elmer). The func-
tion of genes was referred to the ‘National Center for 
Biotechnology Information (NCBI)’s Gene’ and ‘Gene-
Cards’ databases. Because only samples of sufficient 
integrity were further processed for RNA sequencing, 
3 control- ICU patients and 11 COVID-19- ICU patients 
were analysed.
Histology and immunohistochemistry to study myofiber 
structure
Serial cryosections (8 µm thick) were cut from the 
frozen biopsies (perpendicular to diaphragm fiber 
direction) and stained to study (1) myofiber CSA using 
wheat germ agglutinin staining and myofiber type using 
myosin heavy chain antibodies, (2) myofiber nuclei 
using 4',6- diamidino-2- phenylindole staining and (3) 
inflammatory infiltrates using CD45, CD68 and myelop-
eroxidase (MPO) antibodies. To study the striation 
pattern, longitudinal sections were cut and studied by 
α-acting staining (to visualise the z- disc of sarcomeres) 
and by H&E staining (to visualise the overall structure 
of the myofibers in formalin- fixed tissue). Myofiber CSA 
was obtained from ±100 myofibers per type per biopsy 
(analysis of >100 myofibers did not affect the coeffi-
cient of variation (CV) of the CSA). Inflammatory cell 
counts (leucocytes, macrophages and neutrophils) were 
obtained from three random selected viewing fields per 
section per biopsy (0.5 mm2 for fibrosis and 1 mm2 for 
inflammatory cells, respectively). Central nucleus was 
defined as the presence of one nucleus anywhere in the 
sarcoplasm and at least 5 µm inside the sarcolemma.
Statistical analysis
Data were analysed with IBM SPSS Statistics V.22 (IBM) 
and visualised with GraphPad Prism V.7.0 (GraphPad 
Software, USA). For repeated measurements (ie, CSA 
and inflammatory cells), CV was calculated to assess the 
variations in individual patients. Linear mixed model was 
applied with patients as the random factor and group 
as fixed factor to compare the difference between two 
groups of patients. Assumption of normality was tested 
by the Shapiro- Wilk normality test. Log transformation 
was performed if necessary. For non- repeated measure-
ments, the Mann- Whitney U test or Student’s t- test was 
applied for quantitative variables. A χ2 or Fisher’s exact 
test was used to compare qualitative variables. Data were 
expressed as mean (±SEM), median (IQR) or frequen-
cies and percentage, as indicated. We used a two- sided 
significance level of 5% for all analyses.
Patient and public involvement
Patients or the public were not involved in the design, 
conduct, reporting and dissemination plans of our 
research.
RESULTS
Between both groups, there were no significant differ-
ences in the number of days on mechanical ventilation, the 
length of ICU stay, and the administration of neuromus-
cular blocking agents and steroids. None of the patients 
had pre- existing neuromuscular disease or chronic cardi-
opulmonary disease. All patients with COVID-19 were 
admitted to the ICU because of COVID-19 infection and 
required invasive mechanical ventilation. More clinical 
characteristics are in table 1 and online supplemental 
table 1.
First, we investigated gene expression in diaphragm 
tissue from eleven COVID-19- ICU patients and three 
control- ICU patients by RNA sequencing (only samples 
with RNA of sufficient integrity were used). A total of 596 
Table 1 Summary of the demographic and clinical characteristics
Characteristic COVID-19- ICU (n=27) Control- ICU (n=10) P value
Age, year 71 (61–74) 67 (64–73) 0.827
Sex, male (%) 21 (78) 6 (60) 0.248
BMI, kg/m2 27 (26–31) 24 (21–28) 0.014
Duration ICU stay, days 13 (8–27) 11 (3.3–12.3) 0.113
Duration of IMV, days 13 (6–27) 9 (1–12) 0.053
Duration of NMB administration, hours 0 (0–98) 0 (0–240) 0.821
Systemic steroid administration, n (%) 12 (46) 7 (70) 0.182
Maximal CRP, mg/L 310 (260–383) 312 (135–481) 0.969
Data are expressed as median (IQR) or percentage (n, (%). P values were obtained from Mann- Whitney U test or χ2 test. Steroid 
administration was defined as more than 10 mg for >2 days.
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(315 upregulated; 281 downregulated) of 27 647 detected 
genes were differentially expressed (fold- change >±1.5; 
p<0.05; figure 1B). Among the five most upregulated and 
downregulated genes were the small regulatory polypep-
tide of amino acid response (SPAAR, downregulated) 
and the salt inducible kinase (SIK1, upregulated), both 
expressed in the direction of promoting muscle regen-
eration.7 8 However, genes that are known to be involved 
in critical illness- associated muscle atrophy, such as the 
ubiquitin- proteasome and autophagy- lysosome path-
ways,9 were not differentially expressed between groups. 
Gene ontology analysis by protein analysis through evolu-
tionary relationships (PANTHER) revealed upregulation 
of the Fibroblast Growth Factor pathway (as reported 
before,5 and of several pathways involved in inflamma-
tion (figure 1C).
Prompted by the gene expression analyses, 
diaphragm sections were stained to study myofiber 
CSA, inflammatory infiltrates, localisation of myonu-
clei and the striation pattern of the myofibers. The 
distribution of myofiber CSA in COVID-19- ICU 
patients shifted towards larger myofibers compared 
with control- ICU patients (figure 1D). The average 
myofiber CSA was larger in COVID-19- ICU compared 
with control- ICU patients (slow- twitch: 2441±229 vs 
1571±309 µm2, respectively, p=0.008; figure 1Diii/v; 
fast- twitch: 1966±209 vs . 1225±222 µm2, respectively, 
p=0.041; figure 1Div/vi; note that analysis of minimal 
Feret diameter rendered comparable results. Data are 
shown in the online supplement, online supplemental 
figure 1). In COVID-19- ICU patients, the maximum CV 
was 140% for slow- twitch myofiber and 132% for fast- 
twitch myofibers. The average CV, however, was compa-
rable between COVID-19- ICU and control- ICU patients 
(slow- twitch: 49±21% vs 51±12%, respectively, p=0.46; 
fast- twitch: 50±23% vs 48±12%, respectively, p=0.653). 
No significant differences were observed between 
groups for the number of lymphocytes (CD45+), macro-
phages (CD68+) and neutrophilic granulocytes (MPO+) 
(figure 1E).
In four COVID-19- ICU patients (mechanical ventila-
tion duration 5–49 day), we observed diaphragm myofi-
bers with central nuclei (figure 1Fi–iii), indicative of 
myofiber regeneration. Longitudinal sections showed 
that, occasionally, these central nuclei were organ-
ised in ‘trains’ (figure 1Fiii), as frequently observed in 
muscular dystrophies. These four patients also displayed 
extremely large myofibers (CSA >10 000 µm2) and split-
ting of these large myofibers (figure 1Fiv- v), consistent 
with diaphragm myopathy and regeneration, which was 
not present in control- ICU patients. Significant higher 
variation in myofiber CSA was observed in these four 
patients compared with control- ICU patients (CV: slow- 
twitch: 81%±40%; fast- twitch: 90%±32%). Importantly, 
longitudinal sections of the diaphragms showed clear 
striation patterns across these extremely large myofibers, 
indicating increased myofibrillar content rather than the 
accumulation of organelles such as mitochondria or of 
degradation products resulting from postmortem autol-
ysis (figure 1Fvi).
DISCUSSION
The present study reveals distinct pathological changes 
in the diaphragm myofibers of critically ill patients with 
COVID-19. A striking observation was the larger CSA 
of myofibers, which was independent of the duration 
of mechanical ventilation (table 1). It is likely that the 
increased variation of myofiber CSA reflects myofiber 
regeneration and splitting, as supported by the central 
nuclei in myofibers and the RNA sequencing data showing 
DEGs involved in myofiber regeneration. Our previous 
work on these diaphragm samples showed increased 
fibrosis,5 which suggests that the myofiber regeneration 
was—at least partly—pathological. We speculate that these 
pathological changes may impact the contractility of the 
diaphragm in patients with COVID-19, and contribute 
to the persisting sensation of dyspnoea and fatigue that 
a subset of patients experience.6 Myofiber regeneration 
and splitting occurs in response to myofiber injury. The 
aetiology of myofiber injury in COVID-19- ICU patients is 
unclear. It is tempting to speculate that the pathological 
changes might be a direct effect of the virus, as we have 
recently shown that SARS- CoV-2 particles may infiltrate 
diaphragm myofibers,5 but it remains to be established 
whether this affects gene expression. Alternatively, it may 
be explained by a high respiratory drive in mechanically 
ventilated patients with COVID-19,10 as high respiratory 
loading is known to cause diaphragm myofiber injury.11 
However, this was not specifically studied in our patients.
This study has some limitations. First, without non- critically 
ill patients as a control group, it is unclear whether myofi-
bers of COVID-19- ICU patients are less atrophic than those 
of control- ICU patients or are more hypertrophic compared 
with non- critically ill patients. Furthermore, as the current 
study was cross- sectional of nature, we cannot exclude that 
baseline variations affected the study outcomes. Importantly, 
none of the patients had a history of neuromuscular diseases, 
which reduces the possibility of pre- existing diaphragm 
pathology. Second, the number of patients recruited was 
small, particularly for the control- ICU patients (n=10). Conse-
quently, although groups were comparable regarding the 
duration of mechanical ventilation and the use of corticoste-
roids, both risk factors for diaphragm pathology,1 they were 
not for body mass index. Additionally, although proposed as 
a risk factor for diaphragm pathology,1 sepsis was present in 
only three of the control- ICU patients (and in none of the 
COVID-19- ICU patients), thus, it is unlikely that this contrib-
uted to the diaphragm pathology observed in the current 
study. Furthermore, some of the pathological changes were 
observed in a subset of COVID-19- ICU patients. However, 
we have published several studies2–4 that included critically 
ill patients undergoing elective surgery and not in a single 
case did we observe the pathological changes (increased 
variation of myofiber CSA, extremely large myofiber 
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Nevertheless, caution is warranted when drawing conclu-
sions based on these findings. They should be considered 
as hypothesis generating, and future studies should focus on 
the underlying mechanisms and risk factors for these myop-
athic features in the diaphragm. Third, in both groups the 
samples were collected 16–72 hours postmortem, and tissue 
degradation may have occurred. However, the longitudinal 
sections revealed preserved striation pattern (figure 1Fvi), 
indicating that gross myofiber morphology was intact. Finally, 
only 3 of the 10 control- ICU patients had a viral infection, 
which warrants caution when comparing direct effects of 
SARS- CoV-2 with those of other viruses. Furthermore, RNA- 
sequencing analyses were performed in a subset of patients, 
therefore, caution is warranted when relating the findings 
from the RNA- sequencing analyses to those from the histo-
logical analyses.
CONCLUSION
In summary, the diaphragm of deceased COVID-19 
patients shows distinct myopathic changes. Although it 
is unknown whether these changes in the diaphragm 
persist in COVID-19 survivors, it is tempting to speculate 
that they contribute to the ongoing dyspnoea and fatigue 
in those patients.
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Table S1. The demographic and clinical characteristics per patient 

















1 Covid-19  78 Male 27.1 3 3 0 No 122 
2 Covid-19  74 Male 34.6 12 12 288 No 359 
3 Covid-19  64 Male 29.1 8 5 120 No 612 
7 Covid-19  67 Male 30.9 0 0 0 Yes 55 
8 Covid-19  60 Male NA NA NA NA NA NA 
9 Covid-19  41 Male 23.9 68 48 0 Yes 349 
10 Covid-19  74 Male 33.3 37 37 96 Yes 339 
11 Covid-19  72 Male 25.2 13 13 120 Yes 304 
26 Covid-19  74 Male 26.3 31 30 0 Yes 194 
27 Covid-19  68 Female 28.0 26 26 624 No 266 
28 Covid-19 75 Male 25.2 8 7 47 No 258 
29 Covid-19 76 Male 26.0 24 24 0 Yes 332 
30 Covid-19 73 Male 37.0 41 41 240 Yes 262 
31 Covid-19 63 Male 31.4 49 49 104 Yes 310 
32 Covid-19 71 Male 27.0 8 8 0 No 473 
33 Covid-19 65 Male 26.0 9 2 0 Yes 308 
34 Covid-19 60 Female 27.0 24 24 0 No 421 
35 Covid-19 71 Male NA 0 0 0 No NA 
36 Covid-19 73 Male 25.0 12 12 0 Yes 347 
37 Covid-19 78 Male 26.0 17 17 0 No 195 
38* Covid-19 75 Female 28.0 13 13 0 No 300 
39 Covid-19 61 Male 23.0 20 7 0 No 342 
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40 Covid-19 61 Male 37.0 14 14 0 Yes 469 
41 Covid-19 61 Female 33.0 8 8 95 No 438 
42 Covid-19 45 Female 29.4 11 11 41 No 406 
43*  Covid-19 66 Male 22.4 7 5 40 No 162 
44 Covid-19 73 Female 27.5 30 30 20 Yes 274 
Control-ICU patients 
12 
Sepsis after stem cell 
transplantation 65 Male 23.9 12 12 0 Yes 535 
15 
Sepsis after acute 
myeloid leukemia 64 Female 26.0 21 21 0 Yes 536 
16 Influenza Pneumonia 66 Male 21.8 7 0 0 Yes 73 
17 
Sepsis after stem cell 
transplantation 67 Male 20.9 12 12 288 Yes 330 
18 Influenza Pneumonia 51 Male 23.4 4 3 0 Yes 312 
19 
Pulmonary hemorrhage  
72 Female NA NA 1 0 No NA 
20 ARDS after lobectomy 63 Male 30.9 11 10 240 Yes 426 
21 Influenza Pneumonia 70 Female 29.0 10 10 240 Yes 303 
22 
Heart failure after 
aortic dissection 75 Male 21.0 13 7 168 No 196 
24 
Ventricular fibrillation  
83 Female 25.4 1 1 0 No NA 
* Diaphragm specimen used for ACE-2 and SARS-CoV-2 qPCR assays, not for histology and RNAseq 
assays. BMI, body mass index; ICU, intensive care unit; IMV, invasive medical ventilation; NMBA, 
neuromuscular blocking agents; CRP, C-reactive protein. 
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